JAKAVI Tablet
Ruxolitinib (as phosphate)
20 mg
Novartis Pharma AG
| Pack size | 56's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 233.59 AED |
Available as:
Indications
JAKAVI Tablet is used for:
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-pv) myelofibrosis and post-essential thrombocythemia (post-et) myelofibrosis. [lexicomp] myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue)
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ruxolitinib (as phosphate) :
Mechanism of Action
Ruxolitinib is a kinase inhibitor that is selective for the janus associated kinases (jak) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (stat) which modulate gene expression. Patients with myelofibrosis have abnormal jak1 and jak2 activity thus ruxolitinib works to regulate this
Note
JAKAVI 20 mg Tablet manufactured by Novartis Pharma AG. Its generic name is Ruxolitinib (as phosphate). JAKAVI is availble in Saudi Arabia.
Farmaco SA drug index information on JAKAVI Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.